Amino Acid, Peptide, or Protein – Page 49

Enhancing Flu Vaccine Manufacturing and Supply: A Comprehensive Overview

8 months ago talkbio0Tagged Influenza virus vaccine, Manufacture, pandemic preparedness, production, Supply Chain Reliability, Technology, Vaccines

Flu Vaccine Manufacturing, Supply Chain Reliability, Influenza Vaccine Production, Vaccine Manufacturing Technologies, Pandemic Preparedness

AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms

8 months ago talkbio0Tagged AstraZeneca, Clinical Research, Daiichi, Dato-DXd, Datopotamab deruxtecan, Decision, Non-Small Cell Lung Carcinoma, Overall Survival, Sankyo, TROPION-Lung01, United States Food and Drug Administration

AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study

Eli Lilly Appoints Insider Lucas Montarce as Chief Financial Officer Amid Rising Demand for Weight Loss Drugs

8 months ago talkbio0Tagged CFO, Drug Industry, Eli, Eli Lilly, Leadership, Lucas Montarce, Mounjaro, Weight-Loss Agents, Zepbound

Eli Lilly, Lucas Montarce, CFO, weight loss drugs, Mounjaro, Zepbound, pharmaceutical industry, leadership transition

WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

8 months ago talkbio0Tagged Benefit, Continuance of life, EGFR-mutated, first-line, Lazcluze, MARIPOSA, Non-Small Cell Lung Carcinoma, Rybrevant, Tagrisso, WCLC24

Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.

AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks

8 months ago talkbio0Tagged AstraZeneca, Chronic Obstructive Airway Disease, IL33 protein, human, Phase 2 Trials, Respiration Disorders, Tozorakimab

AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases

Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results

8 months ago talkbio0Tagged Glucagon-Like Peptide 1, Laridae, Obesity, Oral cavity, TERN-601, Weight Loss

Terns Pharmaceuticals, Oral GLP-1, Weight Loss, Obesity Treatment, TERN-601

Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%

8 months ago talkbio0Tagged Akeso, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-L1, pembrolizumab, Phase 3 trial, Positive, summit

Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.

AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval

8 months ago talkbio0Tagged ADCs, AstraZeneca, Datopotamab, Deruxtecan, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, TACSTD2 gene, Trodelvy

TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)

Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer

8 months ago talkbio0Tagged amivantamab-vmjw, Chemotherapy-free, Clinical Research, EGFR-mutated lung cancer, Lazcluze, lazertinib, MARIPOSA, Non-Small Cell Lung Carcinoma, osimertinib, Rybrevant, Survival Analysis

Rybrevant (amivantamab-vmjw), Lazcluze (lazertinib), Tagrisso (osimertinib), EGFR-mutated lung cancer, Non-small cell lung cancer (NSCLC), MARIPOSA study, Survival analysis, Chemotherapy-free treatment

GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

8 months ago talkbio0Tagged Asthma, Depemokimab, IL-5 Inhibitor, Inflammation, Long-Acting Biologic, Phase 3 trials, Severe (severity modifier), SmithKline Beecham

GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation